Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
ABT-510 acetate
Contact us for more batch information
ABT-510 acetate
Catalog No. T24997Cas No. 442526-87-6
ABT-510 acetate is an endogenous anti-angiogenic TSP peptide inhibitor, a thrombospondin analog, with anti-inflammatory, anti-cancer and anti-angiogenic activity that induces apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.ABT-510 acetate reduces angiogenesis and inflammatory responses in a mouse model of inflammatory bowel disease. ABT-510 acetate reduces angiogenesis and inflammation in mouse models of inflammatory bowel disease (IBD) and can be used in cancer research, particularly in epithelial ovarian cancer, as well as in inflammatory bowel disease (IBD).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $54 | In Stock | |
| 5 mg | $128 | In Stock | |
| 10 mg | $193 | In Stock | |
| 25 mg | $327 | In Stock | |
| 50 mg | $489 | In Stock | |
| 100 mg | $713 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "ABT-510 acetate"
9-dihydro-13-acetylbaccatin III
Cited
T5132142203-65-4
9-dihydro-13-acetylbaccatin III (9-DHAB III)is an apoptosis inducer. It shows cytotoxicity against the MCF7 cell line and drug-resistant cell line MCF7-ADR.
- $59
Size
QTY
CitedBardoxolone Methyl Cited
T6165218600-53-4
Bardoxolone Methyl (TP-155) is a synthetic triterpenoid that acts as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway with potential anti-tumor and anti-inflammatory activities.
- $39
Size
QTY
CitedL-Ascorbic acid sodium salt
T6674134-03-2
L-Ascorbic acid sodium salt (Vitamin C sodium salt) is a more bioavailable form of vitamin C that is an alternative to taking ascorbic acid as a supplement.
- $42
Size
QTY
PF-573228 Cited
T2001869288-64-2
PF-573228 is an ATP-competitive FAK inhibitor. In a cell-free assay, the IC50 of FAK is 4 nM.
- $45
Size
QTY
CitedPonicidin
T2S197552617-37-5
Ponicidin (Rubescensine B) is a diterpenoid derived from Rabdosia rubescens. Ponicidin exhibits immunoregulatory, anti-inflammatory, anti-viral, and anti-cancer activity. Ponicidin induces apoptosis of gastric carcinoma cells, decreases the phosphorylation of JAK2 and STAT3, and shows no effect on protein levels of JAK2 and STAT3.
- $64
Size
QTY
Voreloxin hydrochloride
T22456175519-16-1
Voreloxin hydrochloride (SNS-595 hydrochloride) is a potent inhibitor of Topoisomerase II with broad-spectrum anti-tumor activity.
- $41
Size
QTY
Cucurbitacin D
TN10133877-86-9
Cucurbitacin D, a triterpenoid isolated from Ecballium elaterium (L.), exhibits anticancer and antitumor activity, inhibits glucose uptake and lactate production in metastatic PrC, and induces inflammasome activation independent of ERK1/2 activation. Cucurbitacin D, a novel inflammasome activator in macrophages, inhibits HepG2 cell proliferation and induces apoptosis by modulating the JAK/STAT3, PI3K/Akt/mTOR and MAPK signaling pathways, and can be used in the study of cervical cancer, leukemia, and prostate cancer.
- $68
Size
QTY
GGTI298 Trifluoroacetate Cited
T68441217457-86-7
GGTI298 Trifluoroacetate (GGTI 298 TFA salt) is a geranylgeranyltransferase I inhibitor with ability to arrest human tumor cells in the G1 phase of the cell cycle and induce apoptosis.
- $79
Size
QTY
CitedNeogambogic acid
T572493772-31-7
Neogambogic acid, an active ingredient in garcinia, can inhibit the growth of some solid tumors and result in an anticancer effect, it may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.
- $46
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | ABT-510 acetate is an endogenous anti-angiogenic TSP peptide inhibitor, a thrombospondin analog, with anti-inflammatory, anti-cancer and anti-angiogenic activity that induces apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.ABT-510 acetate reduces angiogenesis and inflammatory responses in a mouse model of inflammatory bowel disease. ABT-510 acetate reduces angiogenesis and inflammation in mouse models of inflammatory bowel disease (IBD) and can be used in cancer research, particularly in epithelial ovarian cancer, as well as in inflammatory bowel disease (IBD). |
| In vitro | ABT-510 acetate (1, 5, 10, 20, 50 nM; 24 h) induces apoptosis in ID 8 cells and increases the incidence of apoptosis in human epithelial cancer cell lines SKOV3, OVCAR3, and CAOV3.[1] ABT-510 acetate (0-10 μM; 7 days) inhibits NO-stimulated growth and invasion of vascular cells into the extracellular matrix. ABT-510 acetate blocks tumor-driven vascular cell growth, NO-driven cGMP flux, and CD36-mediated fatty acid uptake.[3] |
| In vivo | ABT-510 acetate (100 mg/kg; i.p.; once daily for 90 days) induces apoptosis in vivo and significantly reduces epithelial ovarian tumor size, ascites volume, and secondary lesion spread in mice.[1] ABT-510 acetate (60 mg/kg; subcutaneous osmotic minipump; once daily for 7 days) reduces angiogenesis and inflammation in a mouse model of inflammatory bowel disease.[2] |
| Alias | ABT 510 acetate |
| Molecular Weight | 1054.28 |
| Formula | C48H87N13O13 |
| Cas No. | 442526-87-6 |
| Storage | keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||
| Solubility Information | H2O: 90.0 mg/mL (85.4 mM) | ||||||||||
Solution Preparation Table | |||||||||||
H2O
| |||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.